2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. uri icon

Overview

abstract

  • This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

publication date

  • May 22, 2025

Research

keywords

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • COVID-19 Drug Treatment

Identity

Digital Object Identifier (DOI)

  • 10.1093/cid/ciaf235

PubMed ID

  • 40402009